Breaking News
Sort by:
Top Post
Index Pharmaceuticals Prepares for Commercialisation of Cobitolimod
InDex Pharmaceuticals Holding AB (publ)is planning for self-commercialisation of the drug candidate cobitolimod in the […]
Impact Therapeutics Announces Completion of Series D1 Financing
IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics […]
Exosome-based Company Raised 5 M€ for the Development of Its New Biomedicine and Vaccines
Ciloa, a pioneer company expert in the in vivo customization of exosomes, announced today that […]
NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets
NEC OncoImmunity (NOI), a subsidiary of NEC Corporation (NEC), and VAXIMM AG, a Swiss/German biotech […]
European Investment Bank to Provide a €7.5 Million Loan to Support Further Research and Development of Diadem's AlzoSure® Predict Blood Test for Alzheimer's Disease
The European Investment Bank (EIB) has awarded a €7.5 million loan to Diadem Srl, a […]
AnchorDx Appoints Dr. Marina Bibikova as Chief Scientific Officer
AnchorDx, a world-leading developer of cancer screening and early detection solutions, is delighted to announce that Dr. […]
Tollys and Gustave Roussy Enter into New Research Agreement
Tollys, a biopharmaceutical company developing TL-532, the first anti-cancer immunotherapy based on a synthetic toll-like […]
CELLINK Launches the BIO CELLX, a First of its Kind Biodispensing Platform to Automate 3D Cell Culture
Today CELLINK, A BICO Company, launched the BIO CELLX a novel system that automates 3D […]
BioEcho Life Sciences Receives Growth Equity Investment from Ampersand Capital Partners
BioEcho Life Sciences GmbH, an innovative manufacturer of nucleic acid purification solutions for molecular diagnostics […]
Freenome Launches The Vallania Study For The Early Detection Of Multiple Cancers
Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more